share_log

AbbVie | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

AbbVie | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

艾伯维公司 | 11-K:员工持股年度报告
美股sec公告 ·  06/27 17:04
Moomoo AI 已提取核心信息
AbbVie Inc., a biopharmaceutical company, has filed its Form 11-K annual report with the Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The report details the financial statements of the AbbVie Savings Plan, which is an employee stock purchase, savings, and similar plan. The independent audit, conducted by Ernst & Young LLP, concluded that the financial statements present fairly the net assets available for benefits and the changes in net assets for the year in accordance with U.S. generally accepted accounting principles. The AbbVie Savings Plan's net assets available for benefits increased from $10,305,327 in 2022 to $11,727,168 in 2023. The report includes a summary of the Plan's provisions, contributions, investment options, and distributions, as well as the Plan...Show More
AbbVie Inc., a biopharmaceutical company, has filed its Form 11-K annual report with the Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The report details the financial statements of the AbbVie Savings Plan, which is an employee stock purchase, savings, and similar plan. The independent audit, conducted by Ernst & Young LLP, concluded that the financial statements present fairly the net assets available for benefits and the changes in net assets for the year in accordance with U.S. generally accepted accounting principles. The AbbVie Savings Plan's net assets available for benefits increased from $10,305,327 in 2022 to $11,727,168 in 2023. The report includes a summary of the Plan's provisions, contributions, investment options, and distributions, as well as the Plan's tax status and subsequent events. The Plan is fully compliant with the Employee Retirement Income Security Act of 1974 (ERISA) and offers a variety of investment options, including AbbVie common shares. The Plan's investments are subject to market risks, and the Plan may be terminated at any time by AbbVie, although there are no current intentions to do so. The Plan's tax-exempt status has been affirmed by the IRS, and there are no uncertain tax positions that would require recognition of a tax liability.
生物制药公司AbbVie Inc.已经向美国证券交易委员会(SEC)提交了其截至2023年12月31日的财政年度的11-K表格年度报告。该报告详细记录了AbbVie Savings Plan的财务报表,该计划是一项员工股票购买、储蓄和类似计划。由Ernst & Young LLP进行的独立审计认定,该财务报表根据美国通用会计准则公正呈现可供福利使用的净资产和年度净资产的变化。 AbbVie Savings Plan的可供福利使用的净资产从2022年的10305327美元增加到2023年的11727168美元。报告包括计划条款、缴费、投资选择和分布的摘要,以及计划的税务状态和后续事件。该计划完全...展开全部
生物制药公司AbbVie Inc.已经向美国证券交易委员会(SEC)提交了其截至2023年12月31日的财政年度的11-K表格年度报告。该报告详细记录了AbbVie Savings Plan的财务报表,该计划是一项员工股票购买、储蓄和类似计划。由Ernst & Young LLP进行的独立审计认定,该财务报表根据美国通用会计准则公正呈现可供福利使用的净资产和年度净资产的变化。 AbbVie Savings Plan的可供福利使用的净资产从2022年的10305327美元增加到2023年的11727168美元。报告包括计划条款、缴费、投资选择和分布的摘要,以及计划的税务状态和后续事件。该计划完全遵守1974年的雇员退休收入安全法案(ERISA),并提供包括AbbVie普通股在内的各种投资选择。该计划的投资面临市场风险,AbbVie可以随时终止该计划,尽管目前没有这样的意图。该计划的免税地位已得到美国国税局的确认,也没有需要确认税务负债的不确定税务立场。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息